ZNTL- Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. (ZNTL) has 6 insiders with recent SEC Form 4 filings, including 3 buys and 11 sells. ZNTL is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.51M | $47.83M | - | |
| 10% | 6.46M | $22.87M | - | |
| Other | 146.5K | $518.6K | - | |
| Other | 100.0K | $354.0K | - | |
| CEO | 79.1K | $280.1K | - |
Activity
Buys and sells only
Transactions
10 filings
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Vultaggio Vincent48 | Pao And Pfo | Sell | 40,224 | $2.43 | $97,556.89 | -8.1% | +83.7% | - | |
| Feb 9, 2026 | Eastland Julia Marie53 | CEO &President | Sell | 8,755 | $2.43 | $21,239.31 | -5.2% | +83.7% | - | |
| Feb 9, 2026 | Bruns Ingmar48 | Chief Medical Officer | Sell | 3,297 | $2.43 | $7,998.39 | -4.7% | +83.7% | - | |
| Dec 31, 2025 | Walters Group | 10% Owner | Buy | 6,459,973 | $1.20 | $7,751,967.60 | +91.6% | +73.3% | - | |
| Dec 15, 2025 | Matrix Capital Management Company, LP | 10% Owner | Sell | 7,500,000 | $1.33 | $9,975,000.00 | -53.7% | +93.6% | - | |
| Apr 30, 2025 | Myers Scott Dunseth47 | Director | Buy | 21,000 | $1.40 | $29,372.70 | +8.1% | -4.9% | +182.4% | |
| Feb 6, 2025 | Bruns Ingmar48 | Chief Medical Officer | Buy | 20,000 | $2.28 | $45,656.00 | +120.3% | -43.1% | +10.6% | |
| Feb 3, 2025 | Vultaggio Vincent48 | Pao And Interim Pfo | Sell | 2,615 | $1.71 | $4,475.57 | -1.4% | -19.0% | +67.9% | |
| Feb 3, 2025 | Lackner Mark60 | Chief Scientific Officer | Sell | 14,368 | $1.71 | $24,590.83 | -2.7% | -19.0% | +67.9% | |
| Feb 3, 2025 | Paul Andrea | Chief Legal Officer | Sell | 13,230 | $1.71 | $22,643.15 | -1.2% | -19.0% | +67.9% |
Page 1Next →